NDC 10122-325-01 - Cardene IV
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 10122-325
- Requested NDC
- 10122-325-01
- Package NDCs from labels
- 10122-325-01, 10122-325-10
- Manufacturer
- Chiesi USA, Inc.
- Effective date
- 2020-02-10
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Cardene IV - Chiesi USA, Inc. | Chiesi USA, Inc. | 2020-02-10 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 10122-325-01 | ML - Milliliter | 10122-325 | dff368a9-ed29-45db-84ac-db19fc7880cf | 1 | 2014-04-03 |
| 10122-325-10 | ML - Milliliter | 10122-325 | 7453776b-32e9-4160-beae-5600730dfc98 | 1 | 2014-04-03 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| NICARDIPINE HYDROCHLORIDE | ACTIVE INGREDIENT | K5BC5011K3 | CARDENE IV (NICARDIPINE HYDROCHLORIDE) INJECTION, SOLUTION [CHIESI USA, INC.] | 6 | |
| NICARDIPINE | ACTIVE MOIETY | CZ5312222S | CARDENE IV (NICARDIPINE HYDROCHLORIDE) INJECTION, SOLUTION [CHIESI USA, INC.] | 6 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | CARDENE IV (NICARDIPINE HYDROCHLORIDE) INJECTION, SOLUTION [CHIESI USA, INC.] | 6 | |
| DEXTROSE MONOHYDRATE | INACTIVE INGREDIENT | LX22YL083G | CARDENE IV (NICARDIPINE HYDROCHLORIDE) INJECTION, SOLUTION [CHIESI USA, INC.] | 6 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | CARDENE IV (NICARDIPINE HYDROCHLORIDE) INJECTION, SOLUTION [CHIESI USA, INC.] | 6 | |
| SORBITOL | INACTIVE INGREDIENT | 506T60A25R | CARDENE IV (NICARDIPINE HYDROCHLORIDE) INJECTION, SOLUTION [CHIESI USA, INC.] | 6 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Isolyte S | SODIUM CHLORIDE, SODIUM GLUCONATE, SODIUM ACETATE, POTASSIUM CHLORIDE, AND MAGNESIUM CHLORIDE | B. Braun Medical Inc. | 7e8fe27f-ff82-48c1-9bf6-3c589c8e985d | 2020-05-14 | Warnings, Adverse reactions | 451W47IQ8X |
| Nicardipine Hydrochloride | NICARDIPINE HYDROCHLORIDE | American Regent, Inc. | 76fcb7e0-9034-4fcd-be14-ce7e9ccaee2a | 2020-05-01 | Warnings, Adverse reactions | K5BC5011K3 |
| Nicardipine Hydrochloride | NICARDIPINE HYDROCHLORIDE | Civica, Inc. | 30fb3a4d-fa75-42fd-b4b6-2a21f202027f | 2020-05-01 | Warnings, Adverse reactions | K5BC5011K3 |
| DEXTROSE AND SODIUM CHLORIDE | DEXTROSE MONOHYDRATE, SODIUM CHLORIDE | Fresenius Kabi USA, LLC | b825c9c4-f2fb-4a4a-9d8c-fb020ad07e93 | 2020-04-30 | Warnings, Adverse reactions | 451W47IQ8X LX22YL083G |
| 0.9% SODIUM CHLORIDE | 0.9% SODIUM CHLORIDE | HF Acquisition Co LLC, DBA HealthFirst | a2b8220f-e33a-51c3-e053-2995a90a0734 | 2020-04-07 | Warnings, Adverse reactions | 451W47IQ8X |
| 0.9% SODIUM CHLORIDE | 0.9% SODIUM CHLORIDE | HF Acquisition Co LLC, DBA HealthFirst | a2bba76a-08ce-6902-e053-2995a90ab9c9 | 2020-04-07 | Warnings, Adverse reactions | 451W47IQ8X |
| Dextrose | DEXTROSE MONOHYDRATE | Baxter Healthcare Company | 7de48bdb-9a05-4f2a-bbff-dcfeb284ca6e | 2020-02-27 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose and Electrolyte No. 48 | SODIUM LACTATE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE, MONOBASIC POTASSIUM PHOSPHATE, SODIUM CHLORIDE AND DEXTROSE MONOHYDRATE | Baxter Healthcare Company | b283a454-0c20-4fbf-92d3-dae1f3cd3cad | 2020-02-13 | Warnings, Adverse reactions | 451W47IQ8X LX22YL083G |
| 35a66ebb-329c-49ad-a047-9c0bf15e8028 | 0d58f812-37bf-439f-b3f2-c31f8eefe22e | 2020-02-10 | Warnings, Adverse reactions | 35a66ebb-329c-49ad-a047-9c0bf15e8028 0d58f812-37bf-439f-b3f2-c31f8eefe22e | ||
| Sodium Chloride | SODIUM CHLORIDE | Baxter Healthcare Corporation | fbc01464-8885-4075-af41-911ffec5ae92 | 2020-01-27 | Warnings, Adverse reactions | 451W47IQ8X |
| Sorbitol | SORBITOL | Baxter Healthcare Corporation | aea0b5a1-444b-4330-a3ce-26485dbbfe75 | 2019-12-31 | Warnings, Adverse reactions | 506T60A25R |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | e41adb4e-06fb-4141-ba55-50b043f3c9da | 2019-11-19 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 14445dfd-6041-40cd-a043-3f4da6bcb9c1 | 2019-11-18 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 2557199a-5f60-49d8-b093-1e0700211243 | 2019-11-18 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 794f724c-87f0-49c1-9b26-c9e491978313 | 2019-11-18 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 5c7d3287-883a-459b-9214-074a583c8a59 | 2019-11-18 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 448a1dc5-7a98-4b2f-82af-4b92de05cfc3 | 2019-11-18 | LX22YL083G | |
| Plasma-Lyte A | SODIUM CHLORIDE, SODIUM GLUCONATE, SODIUM ACETATE, POTASSIUM CHLORIDE AND MAGNESIUM CHLORIDE | Baxter Healthcare Corporation | 6ec9e61c-2c26-402f-8604-f446b2e34058 | 2019-08-05 | Warnings, Adverse reactions | 451W47IQ8X |
| DEXTROSE | DEXTROSE MONOHYDRATE | Baxter Healthcare Corporation | 0332f34a-7038-47cc-ba59-d55cad6b73ca | 2019-08-05 | Warnings, Adverse reactions | LX22YL083G |
| Potassium Chloride in Dextrose | POTASSIUM CHLORIDE AND DEXTROSE MONOHYDRATE | Baxter Healthcare Company | 45de5402-5e61-4bbd-8bbc-5e3392c9920e | 2019-07-15 | Warnings, Adverse reactions | LX22YL083G |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.